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ABSTRACT
Stress has an emerging role in cancer and targeting stress-related β-adrenergic 
receptors (AR) has been proposed as a potential therapeutic approach in melanoma. 
Here we report that β3-AR expression correlates with melanoma aggressiveness. In 
addition, we highlight that β3-AR expression is not only restricted to cancer cells, but 
it is also expressed in vivo in stromal, inflammatory and vascular cells of the melanoma 
microenvironment. Particularly, we demonstrated that β3-AR can (i) instruct 
melanoma cells to respond to environmental stimuli, (ii) enhance melanoma cells 
response to stromal fibroblasts and macrophages, (iii) increase melanoma cell motility 
and (iv) induce stem-like traits. Noteworthy, β3-AR activation in melanoma accessory 
cells drives stromal reactivity by inducing pro-inflammatory cytokines secretion and 
de novo angiogenesis, sustaining tumor growth and melanoma aggressiveness.  
β3-ARs also play a mandatory role in the recruitment to tumor sites of circulating 
stromal cells precursors, in the differentiation of these cells towards different 
lineages, further favoring tumor inflammation, angiogenesis and ultimately melanoma 
malignancy. Our findings validate selective β3-AR antagonists as potential promising 
anti-metastatic agents. These could be used to complement current therapeutic 
approaches for melanoma patients (e.g. propranolol) by targeting non-neoplastic 
stromal cells, hence reducing therapy resistance of melanoma.
INTRODUCTION
Several studies suggest that behavioral-related 
factors as catecholamines, hormones released in response 
to stress from the sympathetic nervous system, accelerate 
cancer progression and decrease cancer patient survival 
[1]. Various biological effects of catecholamines in cancer 
cells have been associated to β-adrenergic receptors 
subfamily (β-ARs), composed of three members that 
signal through distinct downstream pathways [2, 3]. 
The three subtypes of β-ARs, β1, β2, and β3, are widely 
expressed in different tumors, such as those of the brain, 
lung, liver, kidney, adrenal gland, breast, ovary, prostate 
or lymphoid tissues [4–7]. We have recently reported that 
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primary melanoma cells express both β1 and β2-ARs and 
that β2-ARs are up-regulated in metastatic melanoma, with 
a strong correlation with malignancy [4]. β3-AR plays 
a key role in the pathophysiology of the cardiovascular 
system and has been recently correlated with de novo 
angiogenesis in models of retinal vascular proliferation 
[8–10]. Moreover, β3-AR mRNA aberrant expression 
has been reported in human cancers, such as leukemia, 
vascular tumors and colon carcinoma [5, 11, 12]. Recently, 
β3-ARs has been found to be expressed by murine 
melanoma B16F10 cells and by endothelial cells of the 
tumor vasculature [13, 14]. Finally, beside deregulation 
of β3-ARs expression, Trp64Arg β3-AR polymorphism 
has been associated with susceptibility to endometrial and 
breast cancers [15, 16].
Although epidemiological data are still contradictory, 
preclinical studies suggest that β-blockers favorably impact 
on disease progression in several types of cancers, mainly 
by reducing metastases, tumor recurrence and mortality, 
[17–19]. In keeping with this, we have previously 
demonstrated a significant activation of pro-tumorigenic 
biological responses induced by catecholamines in 
melanoma cells, severely inhibited by propranolol, a non-
selective inhibitor that can block β-ARs [4]. Although 
propranolol is able to impair key features of melanoma 
malignancy, such as proliferation, motility, secretion 
of metalloproteases, invasiveness and secretion of pro-
angiogenic and pro-inflammatory cytokines, the specific 
contribution of β-ARs in controlling these cellular events 
is still unknown. The ability of catecholamines to induce 
in melanoma cells the expression of the pro-inflammatory 
and pro-angiogenic interleukin-6 (IL-6), interleukin 8 
(IL-8) and vascular endothelial growth factor (VEGF) 
prompted us to study the role of β-AR functions within 
tumor microenvironment [20, 21]. Indeed, tumor 
progression is a multistep process controlled by the cross-
talk between tumor and stromal cells. Stromal cells can be 
either resident or recruited to tumor site from circulating 
bone marrow precursors to sustain tumor growth and to 
orchestrate vasculogenesis, lymphoangiogenesis and 
inflammation [22–24]. The microenvironment supporting 
tumors progression is composed by endothelial cells, 
cancer associated fibroblasts and macrophages (CAFs and 
CAMs), tumor associated lymphocytes and neuthrophils 
[25–27]. Catecholamines are released locally by 
sympathetic nerve fibers or can be found circulating in the 
blood. Although β-ARs could be activated on both tumor 
and stromal cells by catecholamines, data on the role of 
these receptors within the tumor microenvironment are 
needed to develop innovative therapeutic approaches.
Herein we investigated the role of several 
cell populations that compose the melanoma 
microenvironment (i.e. melanoma-associated fibroblasts, 
macrophages, endothelial cells and bone marrow 
derived mesenchymal cells) during cancer progression. 
Our findings indicate a differential involvement of β2 
and β3-ARs in the recruitment and differentiation of 
circulating precursors of stromal cells by the tumor. This 
recruitment sustains tumor inflammation, angiogenesis 
and ultimately promotes melanoma malignancy. Finally, 
our data validate selective β-blockers as effective drugs to 
target both autonomous and non-autonomous oncogenic 
pathways in advanced melanoma.
RESULTS
β3-ARs expression in tissue samples
We have previously described the role of β2-
ARs in melanoma [4]. Here we wanted to address the 
role of β3-ARs expression in melanoma malignancy. 
Consequently, we investigated β3-ARs expression in a 
cohort of human samples of common melanocytic nevi 
(CN), atypical melanocytic nevi (AN), in situ primary 
melanoma (ISM), superficial spreading melanoma (SSM), 
nodular melanoma (NM) and cutaneous and lymph-nodal 
metastatic melanoma (MM). β3-AR was expressed, 
although at various levels, in all examined melanocytic 
lesions. The immunostaining of each group, taking into 
account both staining intensity and percentage of positive 
cells (both composing the score), is shown in Table 1. 
Score 1 was observed in all CN and AN but one (AN) 
which expressed score 2, and in all ISM but one, which 
showed score 2. Score 2 was detected in all SSM and 
NM but one NM, which exhibited score 3. MM showed 
score 3 in four cases and score 2 in six cases. β3-AR score 
was significantly higher in malignant lesions compared to 
nevi (p = 0.000068). ISM + SSM exhibited a significantly 
lower score compared to NM+MM (p = 0.0087), and no 
difference was observed between CN and AN. The cell 
staining intensity of melanocytic/melanoma cells was 
constantly weak, and moderate in only 3 metastases.
Representative β3-AR IHC pictures of melanocytic 
lesions are shown in Fig. 1A. Beside melanoma cells, 
stromal cells show strong immunoreactivity. Granular 
layer of the epidermis, epidermal keratinocytes and 
dermal fibroblasts always showed strong positive reaction. 
Moreover, endothelial cells appeared to be stained in 
all sections. Macrophages and lymphocytic infiltrate 
exhibited reactivity only in invasive malignant lesions 
(Fig. 1B, C).
Taken together, our data show that β3-AR is 
expressed in human melanocytic lesions with a significant 
up-regulation in malignant and advanced malignant 
lesions. Importantly, β3-AR was expressed in stromal, 
endothelial and inflammatory cells (Fig. 1B, C).
In vitro β3-AR expression is affected by hypoxia, 
nutrients and stromal cells contact
Solid tumors initially develop in the absence of 
vascularization and are subjected to various growth 
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Table 1: Immuno-histochemical expression of β3-AR in cutaneous human melanocytic lesions: 
percentage of positivity in each lesion. Each circle represents the percentage of stained cells for one 
lesion. A quarter-black circle indicates positive weak staining; a half-black circle indicates positive 
moderate staining; a three-quarter-black circle indicates positive strong staining; a solid-black circle 
indicates very strong staining.
constraints due to hypoxia and ischemia. This condition 
induces a pleiotropic cellular response that includes 
metabolic adaptation to change in nutrients and oxygen 
supply. We evaluated if β2/β3ARs expression in A375 
human melanoma cells were affected from such conditions 
(i.e. hypoxia and ischemia). 1% oxygen concentration is used 
to mimic in vitro intratumoral hypoxia, changes in glucose 
supply to analyze nutrient sensing and the combination of 
the these factors to mimic ischemic conditions. Our results 
indicate that hypoxia, ischemia and glucose withdrawal lead 
to an upregulation of β3-ARs expression, while β2-ARs 
expression is almost unchanged (Fig. 2A, B, C).
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Figure 1: β3-ARs expression in human samples. (A) β3-ARs expression in human cutaneous melanocytic lesions (X200). β3-AR 
immunostaining in junctional CN (a), AN (b), ISM (c), SSM (d), NM (e), nodal MM (f): all lesions show a low reaction intensity, confined 
to the cell cytoplasm. Epidermal keratinocytes exhibit staining, with strong positivity in granular layer; stromal cells also show reactivity. 
(B) β3-ARs expression in the microenvironment of human cutaneous melanocytic lesions (X400). (a) normal skin adjacent to CN; 
(b) AN; (c) SSM; (d) nodal MM. Arrows point to positive fibroblasts and arrow-heads point to positive blood vessels. Epidermis and 
in particular granular layer show positive reaction. Benign and malignant melanocytes are also stained. (C) Expression of β3-ARs in 
the microenvironment of human cutaneous melanocytic lesions. (a) AN and (b) ISM show melanophages (arrows) negative for β3-AR. 
(c) SSM and (d) nodal MM exhibit macrophages positive for β3-AR staining. Benign and malignant melanocytes are stained.
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Figure 2: β-ARs expression in melanoma cells under various microenvironmental conditions. (A-G) 1 × 106 A375 human 
melanoma cells were serum starved for 24 h and subsequently treated as reported in figure for 24 h. β3 and β2 ARs expression was 
evaluated in total lysates by immunoblotting analysis. Cells were exposed to (A) hypoxia (1%O2); (B) ischemia (1%O2 and 0% glucose); 
(C) hypoglycemia (1 mM) or exposed to CM derived from different activated stromal cells of tumor microenvironment: (D) M1 or M2 
macrophages; (E) HDFs stimulated with TGFβ (myofibroblasts, MFs), as previously reported [55] or (F, G). HUVECs and EPCs exposed 
to hypoxic conditions. Anti-actin immunoblot was used to ensure equal protein loading. The figure is representative of three independent 
experiments.
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Tumor microenvironment is also constituted 
by several accessory cells that may help and sustain 
melanoma progression. We studied the effect of several 
accessory cells, commonly present in solid tumors, on 
β2/3-ARs expression: i) macrophages polarized in vitro 
toward the antitumoral phenotype M1 or toward the pro-
tumoral M2 phenotype [28]; ii) HDFs, activated in vitro 
by transforming growth factor-β1 (TGF-β) to behave as 
MFs; iii) HUVECs and EPCs, as endothelial precursors. 
Endothelial cells were also exposed to 1% O2 hypoxia and 
their conditioned medium was then used to treat A375 
melanoma cells for 24 h to mimic intratumoral hypoxia. 
Our results reveal that accessory cells are not able to affect 
β2-ARs, but they are extremely successful in upregulating 
β3-ARs expression (Fig. 2D, E, F, G). In particular, HDFs, 
M2 macrophages and EPCs cells are the most efficient in 
enhancing β3-ARs expression levels, while exposure to 
hypoxia is able to strengthen the response of all accessory 
cells, including HUVECs (Fig. 2F).
The vast majority of cutaneous melanomas show 
activating mutations in BRAF proto-oncogenes, sustaining 
proliferative stimuli [29, 30]. A375 cell lines are therefore 
a representative model of such melanoma subtype, since 
they show BRAF V600E mutation (REF). In order to study 
the role of β-AR expression and activation in these cells, 
we examined the activation of the extracellular regulated 
kinase (ERK) pathway in response to NE stimulation, in 
the presence or absence of the β3-AR-blocker SR59230A, 
the β2-AR-blocker IC118551, as well as the non-selective 
β-AR-blocker propranolol. The results suggest that ligand 
stimulation of β-ARs by NE is able to enhance basal 
ERK1/2 activation. Importantly, all β-AR blockers tested 
revert this effect, although inhibition of β3-AR appears 
to be the most effective. In addition, we also confirmed 
these results by RNA interference of β2 and β3-ARs 
(Supplementary Fig. 1).
β-ARs in vitro activation drives the recruitment 
of stromal cells to primary melanoma
The ability of primary melanoma cells to recruit 
accessory cells in response to ligand activation of 
β3-AR has been assessed by transwell chemotaxis assay. 
We used HDF and fibroblasts derived from human primary 
melanoma (MAFs). Conditioned medium derived from 
A375 cells stimulated with norepinephrine (NE) for 
24 h elicits an increase in recruitment of HDFs, MAFs, 
HUVECs, as well as MSCs, EPCs and monocytes (Fig. 3) 
when compared to conditioned medium derived from 
unstimulated A375. Ligand stimulation is a mandatory 
step for these recruitments. Indeed, to definitely identify 
the differential role of β2 and β3-ARs, we used two 
different approaches; a pharmacological one by treating 
cells with selective β-AR blockers (i.e. ICI118-551 
for β2-AR and SR-59230A for β3-AR) or by RNA 
interfering with the two β-ARs (Supplementary Fig. 2). 
The results suggested a role of β3-AR in recruiting not 
only fibroblasts (both HDFs and MAFs) but also MSCs 
and monocytes (Fig. 3A, B, E, F). Conversely, β3-AR 
and β2-AR have similar the recruiting abilities towards 
endothelial cells (Fig. 3C, D). Accordingly, only high 
doses of propranolol are active on recruitment of stromal 
cells (Supplementary Fig. 3). To exclude a possible role of 
α1-ARs in attracting stromal cells in vitro, we performed 
HDFs and HUVECs recruitment by conditioned medium 
of NE-treated A375 cells, using the selective α1-adrenergic 
antagonist prazosin. As expected, prazosin has no effect 
on both HDFs and HUVECs recruitment by NE-treated 
melanoma cells (Supplementary Fig. 4A-B).
β3-AR drives accessory cells reactivity and 
enhances melanoma:fibroblasts cross-talk
CAFs have been shown to undergo an activation 
due to contact with cancer cells, consisting in their ability 
to behave as myofibroblasts, contracting collagen fibers 
through expression of α-smooth muscle actin (α-SMA) 
and secreting several pro-inflammatory and proangiogenic 
cytokines, such as IL-6, IL-8, VEGF-A, FGF-2 [24, 26]. 
Both HDFs and MAFs were analyzed for their activation 
in response to NE treatment. The results indicate that: i) 
MAFs show a strong basal α-SMA expression, suggesting 
an activation of these fibroblasts due to the fact that they 
are derived from aggressive cancers, ii) both HDFs and 
MAFs react to NE by increasing their expression of 
α-SMA, although MAFs are less sensitive (Fig. 4A, B). 
Importantly, β3-ARs appear to play the main role in 
the regulation of stromal reactivity, as revealed by 
β2/β3/α1-AR selective antagonists on α-SMA expression 
(Fig. 4A, B, Supplementary. Fig. 4C).
MSCs recruited to tumor sites have been shown to 
escort resident CAFs, as well as endothelial cells in their 
protumoral function, due to their ability to differentiate 
into fibroblasts or to orchestrate vessel-like structures 
[31, 32]. Our results indicate that human bone marrow-
derived MSCs respond to NE treatment with an increase 
in expression of both α-SMA and VEGF receptor-2 
(VEGFR-2) (Fig. 4C), as well as with an enhancement of 
their ability to form vessel-like structures in a capillary 
morphogenesis assay (Fig. 4D).
Stromal reactivity due to tumor progression enhances 
the production of several cytokines by resident fibroblasts 
[33]. In keeping with this, NE is able to induces enhanced 
expression of IL-6, IL-8, VEGF-A and FGF-2 mRNAs 
(Fig. 4E), thereby indicating that the acknowledged ability 
of fibroblasts to orchestrate de novo angiogenesis in vitro 
and to sustain inflammation is enhanced upon catecholamine 
release. We also observed that IL-6 and VEGF-A are able to 
enhance the expression of β3-AR in melanoma cells, while 
β2-AR is upregulated by IL-8, FGF-2 and VEGF-A, thereby 
suggesting a feed-forward loop between NE and its cognate 
receptors β3/ β2-ARs (Fig. 4F).
Oncotarget7www.impactjournals.com/oncotarget
Figure 3: Recruitment of stromal cells. Different stromal cells were allowed to migrate for 24 h toward CM derived from A375 
melanoma cells. In left panels, A375 cells were incubated in the presence or absence of NE (10 μM) and/or β-ARs antagonist ICI 
118-551 (1 μM), SR59230A (10 μM) and propranolol (1 μM). Figure shows recruitment of HDFs (A); MAFs (B); HUVECs (C); EPCs 
(D); MSCs (E) and monocytes (F). The figure is representative of three independent experiments. *P < 0.05, **P < 0.001, ***P < 0.0001 
vs NE stimulated cells.
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Figure 4: In vitro activation of stromal cells by NE. HDFs (A) and MAFs (B) were serum starved for 24 h and then incubated 
in the presence or absence of NE (10 μM) alone and in combination with β-ARs antagonist ICI118-551 (1 μM), SR59230A (10 μM) and 
propranolol (1 μM) for additional 24 h, then αSMA levels were revealed in total lysates by immunoblotting. Anti-actin antibody was used 
to ensure equal protein loading. (C) MSCs were serum starved for 24 h and then incubated in the presence or absence of NE (10 μM) for 
additional 24 h. αSMA and VEGFR-2 levels were analyzed by immunoblotting. Anti-actin immunoblot was used to ensure equal protein 
loading. (D) MSCs were serum starved for 24 h, seeded in Matrigel-coated dishes and incubated with CM from HDFs, treated for 24 h in 
the presence or absence of NE (10 μM) and/or βARs antagonists ICI118-551 (1 μM), SR59230A (10 μM), **P < 0.001 vs NE stimulated 
cells. After 24 h formed capillary were photographed and the number of junctions were counted in 6 fields. Pictures are representative of 
three independent experiments. (E) HDFs were serum starved for 24 h and then incubated with NE (10 μM) for additional 24 h. IL-6, IL-8, 
VEGF-A and FGF2 transcripts were evaluated by quantitative Real-Time PCR as described in Material and Methods. Data represent the 
mean of three independent experiments and are shown as fold change compared to untreated HDFs, *P < 0.05, **P < 0.001. (F) A375 cells 
were serum starved for 24 h and then incubated in the presence or absence of IL-6 (50 ng/ml), IL-8 (50 ng/ml), VEGF-A (50 ng/ml) and 
FGF-2 (50 ng/ml) for additional 24 h. β3 and β2 AR expression was evaluated in total lysates by immunoblotting. Anti-actin immunoblot 
was used to ensure equal protein loading. Figure is representative of three independent experiments.
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β-ARs expression/activation in cancer cells 
enhances their invasiveness and stem-cell 
traits, as well as the ability to favor capillary 
morphogenesis of endothelial cells
To determine the involvement of β-ARs activation 
within the tumor:stroma milieu, we decided to analyze 
in vitro three key functions played by stromal cells, 
i.e. the pro-invasive and pro-angiogenic spur given by 
activated-stromal cells in in vitro co-cultures, as well as 
the ability to enhance stem-like traits in cancer cells. We 
therefore tested the sensitivity of melanoma cells to NE, 
to CM of HDFs activated with NE or to the combination 
of the two treatments. Indeed, we speculated that the 
combination of NE-stimulation of HDFs and of melanoma 
cells, once they have contacted NE-activated stromal 
HDFs and they have undergone enhanced expression of 
β-ARs, should maximize malignancy of melanoma cells. 
In this experimental setting, we assayed the ability of 
melanoma cells to move in a transwell assay. The results 
clearly indicate that HDFs stimulated with NE elicit a 
motile spur in melanoma cells (Fig. 5A), likely due to 
the ability of NE to activate fibroblasts to myofibroblast-
like cells. Furthermore, the pro-migratory effect of NE on 
melanoma and on HDFs is additive (Fig. 5A), suggesting 
a wide function of NE stimulation in the melanoma:stroma 
context.
To correlate this NE-driven mobility to melanoma 
aggressiveness, we also carried out invasion assays of 
melanoma:fibroblasts co-cultures. Quantum-dots-labelled 
melanoma cells were kept in co-culture for 48 h with 
HDFs and stimulate with NE. The results indicate that 
the contact with HDFs enhances the invasive ability of 
melanoma cells (Fig. 5B). The involvement of specific 
β-ARs has been addressed using the specific β-blockers. 
Noteworthy, SR59230A is able to completely revert 
the ability of CAF contact to elicit invasiveness, while 
ICI118-551 is mostly ineffective (Fig. 5B).
Second, we also assayed the capillary morphogenesis 
of HUVECs and EPCs upon contact with NE-treated 
melanoma:fibroblasts co-coltures. Conditioned medium 
from NE-treated co-cultures of melanoma cells:HDFs 
were used in a capillary morphogenesis assay, as an 
indication of endothelial cells commitment towards 
tube-like structures-forming cells. We used mature 
endothelial cells as HUVECs and EPCs, isolated from the 
blood of 3 human umbilical cords and immunophenotyped 
by flow cytometry [34]. Mature endothelial cells have 
been reported to drive de novo angiogenesis, while EPCs 
have been correlated with vasculogenesis, organized by 
tumor-recruited precursors [35]. The results show that 
NE strongly enhances the pro-angiogenic properties 
of melanoma:HDFs co-cultures (Fig. 6A, B). The 
involvement of β-ARs has been addressed using the 
specific β-blockers ICI-118-551 and SR59230A. Both 
antagonists decrease tube-like structure formation for both 
mature and precursors endothelial, although with a main 
implication of β3-ARs (Fig. 6A, B).
Figure 5: Enhancement of tumor cells invasiveness after stromal fibroblast interaction. (A) A375 cells were serum starved 
for 24 h, seeded in Matrigel-coated upper side of the Boyden chambers and allowed to migrate toward CM derived from HDFs, preincubated 
for 24 h with NE (10 μM). The last two samples were exposed again to NE (1 μM) for additional 24 h, ***P < 0.0001 vs standard medium. 
(Continued)
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Figure 5 (Continued): (B) A375 cells were stained with Quantum Dot to render them fluorescent. After 24 h cells were serum starved 
for additional 24 h and seeded in the upper side of Matrigel-coated and then allowed to invade CM derived from HDFs, preincubated in 
the presence or absence of NE (10 μM) and/or βARs antagonist ICI 118-551 (1 μM), SR59230A (10 μM) for 24 h. Bar graphs show the 
mean ± SD of three independent ***P < 0.0001 vs CM from HDFs-NE stimulated.
Figure 6: Endothelial cells reactivity. HUVECs (A) and EPCs
(Continued)
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Besides motile and vessel forming ability of 
melanoma cells in response to NE administration, we 
also investigated whether NE administration could 
induce stem-like traits in cancer cells. The results 
indicate that NE is able to increase expression of 
stemness markers in melanoma cells, such as CD20 and 
CD133 (Fig. 7A, B). P0 and P1 melanosphere formation 
is an acknowledged feature of anchorage-independent 
stem cells. NE administration is able to enhances 
both melanosphere forming ability of A375, therefore 
supporting the role of NE as a stem-like promoting 
factor in melanoma (Fig. 7C, D). The use of selective 
β-blockers suggest that β3-AR is the main receptor 
involved in the melanosphere self-renewal ability of 
A375 cells.
These findings collectively suggest that β3-AR 
affects melanoma malignancy by acting on both cancer 
cells and stromal populations in vitro, coordinating 
angiogenic responses, as well as motility and stem-
cell traits.
DISCUSSION
Here we report that β-ARs are key molecular 
players of melanoma aggressiveness and that their 
function is not restricted to cancer cells, but these 
receptors are strongly expressed and actively functional 
in a large set of tumor associated cells, such as cancer 
associated fibroblasts, macrophages and endothelial 
cells. Indeed, both β-ARs are overexpressed in 
melanoma, with a clear correlation with malignancy. β3-
ARs appear to be the main responsible for instructing 
melanoma cells to respond to environmental cell 
signals, to sense cancer associated fibroblasts and 
macrophages enhancing their motility and stem-like 
traits. Moreover, several accessory cells also express 
β3-AR and its functional activation plays an important 
role in eliciting stromal reactivity, to sustain secretion 
of proinflammatory cytokines and to drive de novo 
angio/vasculogenesis. All these events are promoting 
melanoma aggressiveness. Accordingly, patients-derived 
Figure 6 (Continued) : (B) were serum starved for 24 h, seeded in Matrigel-coated dish and incubated with CM derived from A375 cells, 
co-cultured with HDFs, preincubated in the presence or absence of NE (10 μM) and/or β-ARs antagonist ICI 118-551 (1 μM), SR59230A 
(10 μM) for 24 h. After 24 h, pictures of cells that formed capillaries were taken and number of junctions were counted in 6 fields. Pictures 
are representative of three independent experiments, ***P < 0.0001 vs CM from A375 and HDFs-NE stimulated.
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Figure 7: Cancer stemness induced by NE and HDFs. (A, B) Serum-starved A375 cells were stimulated for 24 h with CM derived 
from HDFs, incubated in the presence or absence of NE (10 μM) and/or β-ARs antagonist ICI 118-551 (1 μM), SR 59230A (10 μM). 
The last two samples were exposed again to NE (1 μM) for additional 24 h. Stem cells marker CD133 (A) and CD20 (B) were analysed 
by cytofluorimetric analysis **P < 0.001 vs NE stimulated cells. (C, D) A375 cells were serum starved for 24 h and incubated with CM 
derived from HDFs, preincubated with βARs antagonist ICI 118 (1 μM), SR59230A (10 μM). Cells were incubated in low-attachment 
dishes to evaluate melanospheres formation. Scale bars represent 100 μm. (C) After 10 days, pictures of P0 melanospheres were taken 
and representative images are shown. (D), P1 individual spheres derived after 10–15 days cultured cells, dissociated from single P0 
melanospheres, were counted. Bar graphs show the mean ± SD of three independent experiments **P < 0.001 vs CM from HDFs-NE 
stimulated.
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tissue showed that β3-ARs is expressed in stromal, 
inflammatory and vascular cells and this expression 
positively correlates with melanoma malignancy.
It is widely accepted that tumor cells do not 
proliferate and progress as isolated entities. In fact, 
they rely on microenvironment support, which include 
extracellular matrix and several supporting stromal cells. 
Cancer cell microenvironment is a strong determinant for 
metastatic potential [23, 24, 27]. Thus, during primary 
tumor formation, tumor cells engage a complex collection 
of mesenchymal cells, jointly forming the tumor-associated 
stroma [31]. As tumor progression proceeds, the stromal 
cells create a “reactive stroma” that releases a variety of 
signals that induce changes in cancer cells phenotype. 
This reactive stroma consists in CAFs, converted into 
myofibroblasts by cancer cell-released factors, endothelial 
cells forming blood-and lymph vessels, as well as 
inflammatory cells (i.e. cancer associated macrophages) 
that are recruited to tumor by cancer secreted chemokines. 
All these host cells engage a continuous molecular cross-
talk with cancer cells, secreting large amounts of factors 
and cytokines that ultimately will influence invasion 
ability and metastasis. Stromal cells can be resident, 
i.e. activated mesenchymal/endothelial cells already 
present within the tissue where the tumor occur, or 
recruited by circulating precursors, mainly derived from 
bone marrow-derived stem cells or monocytes [36–38]. 
Once activated by tumor-released factors, or recruited 
by circulating precursors, these stromal cells are able 
to exert protumoral effects. Indeed, in several cancer 
models CAFs have been reported to induce invasiveness, 
resistance to apoptosis and chemotherapic agents, as well 
as to enhance the stem-cell traits of cancer cells, thereby 
contributing to metastatic spread [39]. Herein, we include 
NE within the large set of soluble factors that can enhance 
stromal reactivity and recruit bone marrow precursors 
(MSCs) to tumor site. So far these characteristics were 
restricted to the pro-inflammatory cytokines IL-6, 
TGF-β and SDF-1. Our findings are therefore novel and 
illustrate a novel interactive circuitry among melanoma 
progression, inflammation and stress. β3-ARs are the 
main effectors of MSCs recruitment, their differentiation 
towards fibroblasts, as well as CAFs reactivity induction. 
In keeping with the role played by CAFs in other cancer 
models, we also observed that β3-ARs expression in CAFs 
is mandatory to enhance invasiveness of melanoma cells, 
as well as to enhance their stem-like traits (e.g. CD133 
and CD20 expression and P1 melanospheres formation).
β-ARs are also involved in monocytes recruitment 
induced by melanoma cells with a main involvement of 
β3-ARs over β2-ARs. Once recruited to the tumor site, 
monocytes differentiate into active macrophages, where 
they may play a multifaceted role for tumor progression. 
Indeed, M1 polarized macrophages are likely to play an 
antitumoral response whereas M2-polarized macrophages 
have been associated with a chronic inflammatory 
response that characterizes several highly malignant 
neoplasiae [40, 41]. In particular, tumor infiltration 
characterized by M2-polarized macrophages has been 
associated with enhanced stromal fibroblasts reactivity 
and angiogenesis, and hence with worst prognosis in 
several cancers [37]. Here we reported that M2-polarized 
macrophages contact induces β3-ARs expression in cancer 
cells, whereas M1-polarized macrophages do not. It is 
also plausible that β3-ARs could play a key role in the 
management of the overall inflammatory response within 
melanoma site. Indeed, catecholamine stimulation could 
enhance melanoma cells release of cytokines, such as 
IL-6, IL-8, VEGF-A and FGF-2, that sustain inflammatory, 
angiogenic and motility tasks. In turn, these cytokines are 
active on melanoma cells to enhance expression of β2-AR 
and β3-AR, thereby closing the circuitry.
Our findings clearly indicate that β-ARs are 
also involved in endothelial cells functions. First, the 
contact with mature endothelial cells or bone marrow 
derived endothelial precursors is able to induce 
β3-ARs expression in melanoma cells, while β2-AR 
levels appear to be unchanged. Catecholamine stimulation 
is able to activate the recruitment by melanoma cells of 
both mature and precursors endothelial cells with a clear 
implication of β3-AR. In vitro capillary morphogenesis 
assays suggest that β3-ARs are likely mediators in both 
angiogenesis and vasculogenesis function, although the 
contribution of β2-ARs is also relevant. In keeping with 
the reported role of stromal fibroblasts in orchestrating 
de novo angiogenesis in several cancer models [42–44], 
HDFs activated by catecholamine administration drive this 
β3-AR-dependent angiogenic response. Hence, there 
is a clear synergy between tumor accessory cells 
(e.g. fibroblasts and macrophages) and endothelial cells, 
possibly sustained by the cross-talk among stress and 
inflammatory factors, driving stromal reactivity and new 
vessels formation. Both these last features are likely 
exploited by malignant cells to succeed metastases.
Stress delivered catecholamines can reach the tumor 
mass via circulating blood or via local sympathetic nerve 
fibers [12, 45, 46]. In support of our data it has been 
shown that chronic stress enhances progression of acute 
lymphoblastic leukemia via β-adrenergic signaling and 
β-blockers can inhibit tumor burden and dissemination 
[12]. Importantly, the authors speculated that β-adrenergic 
signaling may affect the interplay between cancer cells 
and immune or microenvironmental cells, but they 
did not provide mechanistic insight. Additionally, in a 
model of pancreatic cancer, activation of β-adrenergic 
signaling mimics effects similar to chronic stress, and 
pharmacological β-block reverts these effects [47]. Our 
results of β-ARs activation in tumor accessory cells are 
novel and open new perspective for pharmacological 
intervention to prevent melanoma metastases promoted by 
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stress. Indeed, several preclinical and observational studies 
have suggested the possibility that β-ARs blockers, drugs 
originally intended for the treatment of cardiovascular 
disease, may provide new therapeutic opportunities for the 
control of cancer progression, including that of melanoma, 
breast and prostate cancers [48]. Notably, a great reduction 
in the risk of disease progression with β-blockers has been 
reported for melanoma patients [18, 49, 50]. Although 
these studies have been recently questioned [51, 52], 
they promisingly suggest a potential role for targeting 
the β-AR pathway in melanoma patients, indicating the 
need for randomized clinical trials. We herein emphasize 
two key aspects that should be taken into account for 
pharmacological intervention on melanoma: i) β3-AR 
plays an important role in melanoma cell aggressiveness 
suggesting selective β3-AR antagonists as important 
agents in reducing stromal fibroblasts reactivity, ii) non 
neoplastic stromal cells may be also targeted by this 
therapeutic regimen, with the interesting consequence 
to avoid the troublesome resistance to therapy, which is 
typical of cancer cells.
MATERIALS AND METHODS
Materials
Unless specified, all reagents were obtained from 
Sigma; all cytokines used were from Peprotech.
Immunohistochemistry
Forty melanocytic lesions from 40 patients were 
evaluated. Tissue samples were retrieved from the archives 
of the Divisions of Pathology of Pistoia Hospital, Pistoia, 
and of Pathological Anatomy, Department of Surgery 
and Translational Medicine, University of Florence. One 
sample from each case was analysed. The protocol has 
been approved by the Institutional Review Board for the 
use of human tissues. The study series included 5 common 
melanocytic nevi (CN); 5 atypical melanocytic nevi 
(AN); 5 in situ primary melanoma (ISM); 9 superficial 
spreading melanoma (SSM) (thickness 0.30-1.90 mm, 
mean 0.82 mm; 5 level II, 3 level III); 6 nodular melanoma 
(NM) (thickness 1.40-17 mm, mean 5.2 mm; 2 level III, 
3 level IV, 1 level V), 10 metastatic melanoma (MM), 5 
cutaneous and 5 lymph-nodal.
Sections of 4 μm thickness were cut from tissue 
blocks of formalin-fixed, paraffin-embedded samples. 
Immuno-staining was performed according to standard 
procedures. Briefly, antigen retrieval was performed 
by immersing the slides in a thermostat bath containing 
Epitope Retrieval Solution EDTA (pH 8.0) (Bio-Optica, 
Italy) for 20 min at 97°C followed by cooling for 20 min 
at room temperature. Endogenous peroxidase activity was 
blocked with 3% hydrogen peroxide in distilled water 
for 10 min. After blocking with normal horse serum 
(UltraVision, Bio-Optica, Milan, Italy), sections were 
incubated overnight at 4°C with the β3-AR antibody 
(1:100, Thermo Scientific, Milan, Italy). Signal was 
detected by using UltraVision Quanto Detection System 
AP and the bound antibody was visualized using a 
permanent Fast Red as chromogen (Thermo Scientific, 
Milan, Italy). Nuclei were counterstained with Mayer’s 
haematoxylin. Negative control was performed by 
substituting the primary antibody with a non-immune 
serum at the same concentration. Granular layer of the 
epidermis, normal eccrine sweat glands and, at lesser 
extent, sebaceous glands, expressed β3-AR. Eccrine 
sweat gland staining was used as a positive internal 
control (47).
Immunostaining was independently assessed 
by two observers (D.M., S.M.). Discrepancies in the 
reading were resolved by a second parallel reading of 
the slides. The percentage of positive cells per lesion 
was scored according to semi-quantitative criteria. Since 
the percentage of positive nevus melanocytes/melanoma 
cells was always higher than 50%, semi-quantitative 
results were expressed as score 1 (50–80% positive 
nevus melanocytes/melanoma cells), score 2 (81–90% 
nevus melanocytes/melanoma cell staining), and score 3 
(91–100% melanoma cell staining). The cell staining 
intensity was scored on a scale as weak, moderate, 
strong, very strong.
For statistical analysis, non-parametric tests 
were used to determine significant differences between 
groups. The percentage of positive cells per lesion after 
immunological staining in each group was the unit of 
analysis. Groups were: nevi, primary melanoma, MM. 
Statistical evaluation was performed comparing nevi 
versus malignant lesions, ISM + SSM versus NM+MM, 
CN versus AN. Differences were assessed using the Fisher 
test and were considered significant at p ≤ 0.05.
Cell cultures and transfections
A375 human melanoma cells were from ATCC. 
Cells were grown in DMEM containing 10% FBS and 
10 U/ml penicillin and 10 mg/ml streptomycin. MSCs 
were isolated from bone marrow aspirated of three 
different human volunteers, following donor consent. 
Cells were grown in in T75 cm2 with low glucose DMEM 
(1 mM glucose). Experiments under hypoxic conditions 
(1% O2) were performed in the hypoxic incubator. Human 
monocytes were obtained from normal donor buffy coat 
by gradient centrifugation using Ficoll and macrophages 
were polarized as described by Comito and colleagues 
[37]. For transient transfections, A375 cells were 
plated in 60-mm cell culture dishes and grown to 80% 
confluence. The siRNA (Life Technologies) was diluted 
to a final concentration of 20nM. Transfections were 
performed using Lipofectamine (Invitrogen), following 
manufacturer’s recommendations.
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Isolation of human dermal fibroblasts (HDFs) 
and melanoma associated fibroblasts (MAFs)
HDFs were isolated from healthy leg regions of 
volunteers. MAFs were isolated from patients diagnosed 
with primary melanoma placed in the back dorsal zone. 
A small piece of the tumor tissue was minced into <1 
mm pieces in size and digested overnight in 1 mg/mL 
collagenase I at 37°C. They were then spun down, 
re-suspended and plated into complete medium. We also 
excluded contamination by skin stem cells of HDFs, by 
evaluation of CD34 and cytokeratin-15, established skin 
stem cell markers [53].
Endothelial cells isolation and characterization
Human umbilical cord blood from healthy newborns 
with a number of total nucleated cells <1.5 × 109 was 
chosen in accomplishment with rules of Umbilical Cord 
Bank of Careggi Hospital (Florence, Italy), with maternal 
informed consent, in accordance with the Declaration of 
Helsinki and in compliance with Italian law. Endothelial 
precursors cells (EPCs) have been isolated from Umbilical 
Cord Bank as reported in Margheri et al [54]. Briefly, 
blood was diluted 1:1 with Hanks balanced salt solution 
and was overlaid on an appropriate volume of density 
gradient separation medium. Cells were centrifuged for 
30 minutes at room temperature at 740g. Mononuclear 
cells were recovered, washed 3 times with Hanks balanced 
salt solution and resuspended in complete EGM-2 
medium, supplemented with 10% FBS, 50 ng/mL VEGF, 
and 5 IU/mL heparin. Cells were seeded on gelatin-coated 
6-well tissue culture plates at a density of 5 × 105 cells/
cm2 in a 5% CO2 humidified incubator at 37°C. On days 
4 and 7, half of the medium was exchanged with fresh 
medium. Then the medium was changed completely with 
EGM2–10% FBS every 3 days. EPC colonies appeared 
in cell cultures after 2–3 weeks and were identified as 
circumvented monolayers of cobblestone-like cells. EPCs 
were analyzed for the expression of surface antigens 
by flow cytometry (CD45, CD34, CD31, CD105/R, 
VEGF-R2).
Preparation of conditioned media
Conditioned media (CM) were obtained from HDFs, 
MAFs, MSCs or macrophages. Cells were grown to sub-
confluence, then serum starved and incubated for 48 h 
before collection of the CM. CM were harvested, clarified 
by centrifugation, and used freshly.
Western blot analysis
Cells derived from our experimental conditions 
were lysed for 20 min on ice in 500 μl of RIPA lysis 
buffer. 20 μg of total proteins were loaded on SDS–PAGE, 
separated and transferred onto nitrocellulose (Millipore). 
The immunoblots were incubated in 3% bovine serum 
albumin, 10 mmol/L Tris–HCl (pH 7.5), 1 mmol/L EDTA, 
and 0.1% Tween 20 for 1 h at room temperature, probed 
first with specific antibodies and then with appropriate 
secondary antibodies.
In vitro boyden invasion assay
Transwells (Costar), equipped with 8-μm-pore 
polyvinylpyrrolidone-free polycarbonate filters, were 
coated with 50 μg/cm2 of reconstituted Matrigel (BD). 
Cells were loaded into the upper compartment (5 × 104 
cells in 200 μl) in serum-free growth medium. Cells were 
allowed to migrate towards complete growth medium 
or medium conditioned by stromal cells. After 24 h of 
incubation at 37°C, non-invading cells were removed 
mechanically using cotton swabs, and the membrane was 
stained with Diff-Quick solution and chemoattracted cells 
were counted.
Capillary morphogenesis assay
All the experiments were performed using growth 
factor–reduced Matrigel at a concentration of 1 mg/mL. 
Fifty microliters of Matrigel was added to each well of a 
96-well plate and then placed in a humidified incubator 
at 37°C for 30 min. HUVECs and EPCs (2 × 104 cells/ 
well) were added to the Matrigel-coated plates in a final 
volume of 200 μL. The effects on the morphogenesis of 
endothelial cells were recorded after 6 h with an inverted 
microscope (Leitz DM-IRB) equipped with CCD optics 
and a digital analysis system. Results were quantified by 
measuring the joint numbers in the field.
Real time PCR
Total RNA from cells was isolated using RNeasy 
plus Mini Kit (Qiagen). 1 μg of total RNA was used 
for Reverse transcription using QuantiTect reverse 
transcription Kit (Qiagen). Measurement of gene 
expression was performed by quantitative real-time PCR 
(7500 Fast Real-Time PCR System, Applied Biosystems) 
using Quantifast SYBR Green PCR (Qiagen). The 
amount of target is normalized to an endogenous 
reference (GAPDH). The primers for VEGF-A were: 
5′TTCTGCTGTCTTGGGTGCAT-3′ (forward), 
5′TGTCCACCAGGGTCTCGATT-3′ (backward). The 
primers for IL-8 were 5′-CTGGCCGTGGCTCTCTTG-3′ 
(forward), 5′-TTAGCACTCCTTGGCAAAACTG-3′ 








A375 cells incubated for 72 h with CM were 
detached using Accutase (Sigma). For melanospheres 
formation, single cells were plated at 150 cells/cm2 on 
low attachment 100 mm plate (Corning) in DMEM/F12 
(Invitrogen, Carlsbad, CA, USA) supplemented with 
N2 (Invitrogen), 20 μg/ml insulin, 10 ng/ml bFGF and 
10 ng/ml EGF. Cells were grown under these conditions 
for 15–20 days and formed non-adherent P0 spheres. For 
the evaluation of self-renewal a single melanosphere was 
dissociated in single cells with Accutase and a dilution of 
one cell per well into 96-well low attachment plates was 
performed in order to isolate individual P1 melanospheres.
Flow cytometry
1 × 106 A375 cells were labelled with FITC- anti-
CD133 (human clone: AC133) and PE-anti-CD20 
[EP459Y] antibodies for 1 h at 4°C in the dark. Cells 
were washed and flow cytometry was performed using a 
FACSscan (BD Biosciences).
Statistical analysis
Data are presented as means ± SD from at least three 
independent experiments. Statistical analysis of the data 
was performed by Student’s t test. P-values of ≤ 0.05 were 
considered statistically significant.
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